Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER + breast cancer cells

Sudharsan Periyasamy Thandavan, William H. Jackson, Julia S. Samaddar, Brian Erickson, John Ryan Barrett, Lauren Raney, Elangovan Gopal, Vadivel Ganapathy, William D Hill, Kapil N. Bhalla, Patricia V Schoenlein

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

In recent studies, we and others showed that autophagy is critical to estrogen receptor positive (ER+) breast cancer cell survival and the development of antiestrogen resistance. consequently, new approaches are warranted for targeting autophagy in breast cancer cells undergoing antiestrogen therapy. Because crosstalk has been demonstrated between the autophagy- and proteasome-mediated pathways of protein degradation, this study investigated how the proteasome inhibitor bortezomib affects autophagy and cell survival in antiestrogen-treated ER+ breast cancer cells. Bortezomib, at clinically achievable doses, induced a robust death response in ER+, antiestrogen-sensitive and antiestrogen-resistant breast cancer cells undergoing hormonal therapy. cleavage of PARP and lamin A was detectable as a read-out of cell death, following bortezomib-induced mitochondrial dysfunction. Prior to induction of cell death, bortezomib-treated cells showed high levels of light chain 3 (LC3) and p62, two protein markers for autophagy. The accumulation of these proteins was due to bortezomib-mediated blockade of long-lived protein turnover during macroautophagy. This novel action of bortezomib was linked to its blockade of cathepsin-L activity, which is required for autolysosomal- mediated protein turnover in ER+ breast cancer cells. Further, bortezomib-treated breast cancer cells showed induction of the unfolded protein response, with upregulation of CHOP and GRP78. Bortezomib also induced high levels of the pro-apoptotic protein BNIP3. Knockdown of CHOP and/or BNIP3 expression via RNAI targeting significantly attenuated the death-promoting effects of bortezomib. Thus, bortezomib inhibits prosurvival autophagy, in addition to its known function in blocking the proteasome, and is cytotoxic to hormonally treated eR+ breast cancer cells. These findings indicate that combining a proteasome inhibitor like bortezomib with antiestrogen therapy may have therapeutic advantage in the management of early-stage breast cancer.

Original languageEnglish (US)
Pages (from-to)19-35
Number of pages17
JournalAutophagy
Volume6
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Cathepsins
Endoplasmic Reticulum Stress
Estrogen Receptor Modulators
Autophagy
Caspases
Cell Death
Breast Neoplasms
Proteasome Inhibitors
Proteasome Endopeptidase Complex
Cell Survival
Proteins
Bortezomib
Lamin Type A
Cathepsin L
Unfolded Protein Response
Apoptosis Regulatory Proteins
Therapeutics
Estrogen Receptors
Proteolysis
Up-Regulation

Keywords

  • Autophagy
  • BNIP3
  • Bortezomib
  • Cathepsins
  • ER stress
  • Protein turnover
  • Tamoxifen

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER + breast cancer cells. / Periyasamy Thandavan, Sudharsan; Jackson, William H.; Samaddar, Julia S.; Erickson, Brian; Barrett, John Ryan; Raney, Lauren; Gopal, Elangovan; Ganapathy, Vadivel; Hill, William D; Bhalla, Kapil N.; Schoenlein, Patricia V.

In: Autophagy, Vol. 6, No. 1, 01.01.2010, p. 19-35.

Research output: Contribution to journalArticle

Periyasamy Thandavan, Sudharsan ; Jackson, William H. ; Samaddar, Julia S. ; Erickson, Brian ; Barrett, John Ryan ; Raney, Lauren ; Gopal, Elangovan ; Ganapathy, Vadivel ; Hill, William D ; Bhalla, Kapil N. ; Schoenlein, Patricia V. / Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER + breast cancer cells. In: Autophagy. 2010 ; Vol. 6, No. 1. pp. 19-35.
@article{5114159557dc4588abfa4f4bd3af8129,
title = "Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER + breast cancer cells",
abstract = "In recent studies, we and others showed that autophagy is critical to estrogen receptor positive (ER+) breast cancer cell survival and the development of antiestrogen resistance. consequently, new approaches are warranted for targeting autophagy in breast cancer cells undergoing antiestrogen therapy. Because crosstalk has been demonstrated between the autophagy- and proteasome-mediated pathways of protein degradation, this study investigated how the proteasome inhibitor bortezomib affects autophagy and cell survival in antiestrogen-treated ER+ breast cancer cells. Bortezomib, at clinically achievable doses, induced a robust death response in ER+, antiestrogen-sensitive and antiestrogen-resistant breast cancer cells undergoing hormonal therapy. cleavage of PARP and lamin A was detectable as a read-out of cell death, following bortezomib-induced mitochondrial dysfunction. Prior to induction of cell death, bortezomib-treated cells showed high levels of light chain 3 (LC3) and p62, two protein markers for autophagy. The accumulation of these proteins was due to bortezomib-mediated blockade of long-lived protein turnover during macroautophagy. This novel action of bortezomib was linked to its blockade of cathepsin-L activity, which is required for autolysosomal- mediated protein turnover in ER+ breast cancer cells. Further, bortezomib-treated breast cancer cells showed induction of the unfolded protein response, with upregulation of CHOP and GRP78. Bortezomib also induced high levels of the pro-apoptotic protein BNIP3. Knockdown of CHOP and/or BNIP3 expression via RNAI targeting significantly attenuated the death-promoting effects of bortezomib. Thus, bortezomib inhibits prosurvival autophagy, in addition to its known function in blocking the proteasome, and is cytotoxic to hormonally treated eR+ breast cancer cells. These findings indicate that combining a proteasome inhibitor like bortezomib with antiestrogen therapy may have therapeutic advantage in the management of early-stage breast cancer.",
keywords = "Autophagy, BNIP3, Bortezomib, Cathepsins, ER stress, Protein turnover, Tamoxifen",
author = "{Periyasamy Thandavan}, Sudharsan and Jackson, {William H.} and Samaddar, {Julia S.} and Brian Erickson and Barrett, {John Ryan} and Lauren Raney and Elangovan Gopal and Vadivel Ganapathy and Hill, {William D} and Bhalla, {Kapil N.} and Schoenlein, {Patricia V}",
year = "2010",
month = "1",
day = "1",
doi = "10.4161/auto.6.1.10323",
language = "English (US)",
volume = "6",
pages = "19--35",
journal = "Autophagy",
issn = "1554-8627",
publisher = "Landes Bioscience",
number = "1",

}

TY - JOUR

T1 - Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER + breast cancer cells

AU - Periyasamy Thandavan, Sudharsan

AU - Jackson, William H.

AU - Samaddar, Julia S.

AU - Erickson, Brian

AU - Barrett, John Ryan

AU - Raney, Lauren

AU - Gopal, Elangovan

AU - Ganapathy, Vadivel

AU - Hill, William D

AU - Bhalla, Kapil N.

AU - Schoenlein, Patricia V

PY - 2010/1/1

Y1 - 2010/1/1

N2 - In recent studies, we and others showed that autophagy is critical to estrogen receptor positive (ER+) breast cancer cell survival and the development of antiestrogen resistance. consequently, new approaches are warranted for targeting autophagy in breast cancer cells undergoing antiestrogen therapy. Because crosstalk has been demonstrated between the autophagy- and proteasome-mediated pathways of protein degradation, this study investigated how the proteasome inhibitor bortezomib affects autophagy and cell survival in antiestrogen-treated ER+ breast cancer cells. Bortezomib, at clinically achievable doses, induced a robust death response in ER+, antiestrogen-sensitive and antiestrogen-resistant breast cancer cells undergoing hormonal therapy. cleavage of PARP and lamin A was detectable as a read-out of cell death, following bortezomib-induced mitochondrial dysfunction. Prior to induction of cell death, bortezomib-treated cells showed high levels of light chain 3 (LC3) and p62, two protein markers for autophagy. The accumulation of these proteins was due to bortezomib-mediated blockade of long-lived protein turnover during macroautophagy. This novel action of bortezomib was linked to its blockade of cathepsin-L activity, which is required for autolysosomal- mediated protein turnover in ER+ breast cancer cells. Further, bortezomib-treated breast cancer cells showed induction of the unfolded protein response, with upregulation of CHOP and GRP78. Bortezomib also induced high levels of the pro-apoptotic protein BNIP3. Knockdown of CHOP and/or BNIP3 expression via RNAI targeting significantly attenuated the death-promoting effects of bortezomib. Thus, bortezomib inhibits prosurvival autophagy, in addition to its known function in blocking the proteasome, and is cytotoxic to hormonally treated eR+ breast cancer cells. These findings indicate that combining a proteasome inhibitor like bortezomib with antiestrogen therapy may have therapeutic advantage in the management of early-stage breast cancer.

AB - In recent studies, we and others showed that autophagy is critical to estrogen receptor positive (ER+) breast cancer cell survival and the development of antiestrogen resistance. consequently, new approaches are warranted for targeting autophagy in breast cancer cells undergoing antiestrogen therapy. Because crosstalk has been demonstrated between the autophagy- and proteasome-mediated pathways of protein degradation, this study investigated how the proteasome inhibitor bortezomib affects autophagy and cell survival in antiestrogen-treated ER+ breast cancer cells. Bortezomib, at clinically achievable doses, induced a robust death response in ER+, antiestrogen-sensitive and antiestrogen-resistant breast cancer cells undergoing hormonal therapy. cleavage of PARP and lamin A was detectable as a read-out of cell death, following bortezomib-induced mitochondrial dysfunction. Prior to induction of cell death, bortezomib-treated cells showed high levels of light chain 3 (LC3) and p62, two protein markers for autophagy. The accumulation of these proteins was due to bortezomib-mediated blockade of long-lived protein turnover during macroautophagy. This novel action of bortezomib was linked to its blockade of cathepsin-L activity, which is required for autolysosomal- mediated protein turnover in ER+ breast cancer cells. Further, bortezomib-treated breast cancer cells showed induction of the unfolded protein response, with upregulation of CHOP and GRP78. Bortezomib also induced high levels of the pro-apoptotic protein BNIP3. Knockdown of CHOP and/or BNIP3 expression via RNAI targeting significantly attenuated the death-promoting effects of bortezomib. Thus, bortezomib inhibits prosurvival autophagy, in addition to its known function in blocking the proteasome, and is cytotoxic to hormonally treated eR+ breast cancer cells. These findings indicate that combining a proteasome inhibitor like bortezomib with antiestrogen therapy may have therapeutic advantage in the management of early-stage breast cancer.

KW - Autophagy

KW - BNIP3

KW - Bortezomib

KW - Cathepsins

KW - ER stress

KW - Protein turnover

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=75149129645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149129645&partnerID=8YFLogxK

U2 - 10.4161/auto.6.1.10323

DO - 10.4161/auto.6.1.10323

M3 - Article

VL - 6

SP - 19

EP - 35

JO - Autophagy

JF - Autophagy

SN - 1554-8627

IS - 1

ER -